Last updated: July 8, 2026
SUPERNUS v. Macleods (2:25-cv-15399): Litigation Summary, Patent Claims, and What It Means for Generic Entry
SUPERNUS PHARMACEUTICALS, INC. is enforcing patent rights in a Hatch-Waxman case against MACLEODS PHARMACEUTICALS LTD. in 2:25-cv-15399 (filed 2025). The docket indicates an active dispute tied to an FDA ANDA-type challenge, with the core business question centered on whether Macleods’ generic product is blocked by asserted Orange Book-listed patents and whether any claim survives invalidity and non-infringement defenses.
No complete and accurate patent-level litigation facts (asserted patent numbers, claims, product/ANDA reference, Paragraph IV basis, parties’ specific positions, claim construction rulings, settlement terms, or dispositive orders) are present in the provided input. Without those docket-specific details, a patent-by-patent summary would risk incorrect identification of the asserted estate and the litigation’s actual status.
What does the SUPERNUS PHARMACEUTICALS v. MACLEODS PHARMACEUTICALS case (2:25-cv-15399) allege?
A correct litigation summary must tie the infringement allegations to:
- the ANDA/NDA reference listed drug (RLD)
- the Orange Book patents asserted (patent numbers)
- the theories of infringement (literal infringement, infringement under the doctrine of equivalents, method-of-use vs composition, formulation vs manufacturing)
- the Paragraph IV posture (whether the case is a 21 USC §355(j)(2)(A) scheme dispute)
- the specific claim numbers being asserted
Those elements are not included in the provided information, so the allegations cannot be stated accurately.
Which patents are listed in the complaint and what claims are asserted?
Not available from the provided input. Patent numbers and asserted claims are required for an accurate “what is protected” and “how strong is the patent estate” analysis.
Is the case about formulation, method-of-use, or manufacturing?
Not available from the provided input. Without asserted claim types and claim language, classification would be speculative.
When did SUPERNUS sue, and what is the case timeline for 2:25-cv-15399?
A timeline requires:
- complaint filing date
- service date(s)
- answer and responsive pleading dates
- any motions to dismiss, preliminary injunction motions, or summary judgment dates
- Markman/claim construction milestones
- trial dates (if any)
- latest docket event and current posture (pending, stayed, settled)
The provided input does not contain these docket events, so no verified timeline can be produced.
How does Paragraph IV litigation in 2:25-cv-15399 affect FDA approval and tentative generic launch?
To answer this, the analysis must be anchored to:
- the ANDA’s “section” timing (Paragraph IV suit timing under 21 USC §355(j)(5)(B)(iii))
- whether a 30-month stay is triggered or lifted
- whether litigation ends in entry with carve-outs or settlement
- whether any exclusivity (PTE/552) affects the stay timing
The provided input does not identify the RLD, ANDA number, or stay/eligibility dates.
What is the Orange Book status of the patents at issue in SUPERNUS v. MACLEODS?
Orange Book analysis requires:
- the RLD name
- the specific patent list for that RLD (U.S. patents, expiration dates, regulatory exclusivities)
- which patents were listed as “F” (FDA-listed) and whether the case asserted “B” or “C” type patents
- whether any patents expire before any remaining regulatory exclusivity
None of these details are present in the provided input.
How strong is the patent estate in SUPERNUS v. MACLEODS (2:25-cv-15399)?
A strength assessment requires:
- asserted patent families and their remaining expiration
- claim construction indicators
- prior art landscape (obviousness and written description enablement)
- enablement and best mode issues (as applied)
- litigation history for the same patent(s)
Because asserted patent numbers and claim content are not provided, a strength assessment cannot be stated accurately.
What patents protect the relevant SUPERNUS product against Macleods, and how many are asserted?
This section must identify:
- the active ingredient(s)
- the dosage form(s) at issue
- the number of Orange Book-listed patents asserted
- whether asserted claims are composition, formulation, or method-of-use
The provided input does not specify the product or patents.
Which companies are challenging or defending, and what does each side’s strategy suggest?
A real analysis includes:
- SUPERNUS’s enforcement posture (early injunction seeks vs damages-focused)
- Macleods’s defenses (invalidity arguments, non-infringement, carve-out design-arounds)
- whether claim construction favors either side
No strategic positions or docket motion outcomes are provided.
What claim construction and pretrial rulings affect infringement and validity in 2:25-cv-15399?
Markman outcomes and intermediate orders often decide the case. Without:
- claim terms construed
- infringement mapping outcomes
- prior art determinations
- summary judgment decisions
- evidentiary rulings
this cannot be completed accurately.
Did the parties settle, and what are the key settlement and licensing terms?
Settlement analysis requires:
- whether a consent judgment or stipulated dismissal was filed
- licensing agreement terms (if any) such as royalty structure, field-of-use, effective launch date
- carve-outs or “at-risk” launch permission scope
- dismissal with prejudice vs without prejudice
No settlement information is present in the provided input.
What generic entry risks exist for Macleods if SUPERNUS wins or loses in 2:25-cv-15399?
Entry-risk analysis needs:
- remaining patent term at time of decision
- whether any asserted patents are held unenforceable/invalid
- whether non-infringement is found on a critical claim subset
- whether any remaining patents still block launch
Those inputs are not provided.
Biosimilar risk and biologic-specific defenses: is 2:25-cv-15399 a biosimilar case?
Not determinable from the provided input.
Key Takeaways
- A verified, patent-level litigation summary for SUPERNUS PHARMACEUTICALS, INC. v. MACLEODS PHARMACEUTICALS LTD., 2:25-cv-15399 requires docket-specific details (asserted patent numbers, asserted claims, RLD/ANDA identity, and procedural milestones).
- The provided input does not contain those required facts; producing a litigation summary that names specific patents, maps infringement, or states current posture would be incomplete and risks inaccuracy.
FAQs
- What information must be pulled from the complaint to summarize a Hatch-Waxman case like 2:25-cv-15399?
- How do asserted Orange Book patents determine the scope of a 30-month ANDA stay?
- What procedural milestones in ANDA litigation most affect expected launch timing?
- How do claim construction outcomes change infringement probability in generic patent suits?
- What settlement terms typically appear in stipulated dismissals after Paragraph IV litigation?
References
- U.S. District Court, District of New Jersey (or applicable district), SUPERNUS PHARMACEUTICALS, INC. v. MACLEODS PHARMACEUTICALS LTD., Civil Action No. 2:25-cv-15399.
